{"name":"Inotiv","slug":"inotiv","ticker":"NOTV","exchange":"NASDAQ","domain":"inotivco.com","description":"Inotiv, Inc. is a contract research organization organized in Indiana and headquartered in Lafayette, Indiana. The company operates two core business units: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy for small molecule drug candidates, biotherapeutics, and biomedical devices. The RMS business unit provides research models, lab animal diets and bedding and support services.","hq":"West Lafayette, IN","founded":0,"employees":"1945","ceo":"Robert Leasure Jr.","sector":"Preclinical CRO / Research Models","stockPrice":0.31,"stockChange":0,"stockChangePercent":0,"marketCap":"$11M","metrics":{"revenue":547656000,"revenueGrowth":-5.4,"grossMargin":22.9,"rdSpend":405000,"netIncome":-68625000,"cash":15180000,"dividendYield":0,"peRatio":-6.2,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"NOTV-001 patent cliff ($0.0B at risk)","drug":"NOTV-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Inotiv Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Inotiv reported its fourth quarter and full year 2023 financial results, with revenue of $123.8 million and a net loss of $13.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Inotiv Announces Acquisition of BioSmart Technologies","summary":"Inotiv acquired BioSmart Technologies, a provider of in vitro testing services, to expand its capabilities in the preclinical CRO market.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOZEgyMU1NX2tlOWNJNFM3d0Q1bTZFZURCZ0tPS0JhenMxNldJREh2MWV6MW9tZWs1NEI1UnNVOV9CbnYyRnlhb0VwdlZfSWpvNEdseE1ocTRGcVRjeGI0eW4xN1pkVEdqTktQN3laVTh3cTFGRkk0ckhyWVVTQlhmZTdsVTBaV1ZSZUpXZkxn?oc=5","date":"2026-03-03","type":"pipeline","source":"Yahoo Finance","summary":"How Inotiv (NOTV) Narrative Is Shifting As Analysts Reset Fair Value Expectations - Yahoo Finance","headline":"How Inotiv (NOTV) Narrative Is Shifting As Analysts Reset Fair Value Expectations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMXFURkEwRUthZXNKa0xBU01pYXlvQ1BrWGNsMEhTNzcxa0w0cWtiekpDLXhmZzN1ejJlQkVyeFEyUGVySmxMeGFVOUdRZThmem1pa0lHNkxvT3pLakZyV0tVSi1TMm9pWjRtMnRJTjNwRXI3blAtb2dyQzg3WXM0R0dKQlBIemoydWfSAY8BQVVfeXFMTjd0MklRSTlhRVlPYWxEMV8wZzE0Zk5ISmNjTzJBU3BGcFBoNnE3cGhPUDRSOVBhdWZ2RGlJSjZMVlBuWEpndUwyS0dBemwtdWpkc3JpNm54djZWMnM3cEZtck1mWDNRNFlyamUyZkJFeHNWYW5tendkOXdadXEzdzF1TjMycUp1dUlhOHNjUVE?oc=5","date":"2026-02-09","type":"earnings","source":"AlphaStreet","summary":"Inotiv Q1 2026 Earnings Soar: DSA Segment Surge Stuns - AlphaStreet","headline":"Inotiv Q1 2026 Earnings Soar: DSA Segment Surge Stuns","sentiment":"positive"},{"date":"2026-02-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOejVya1R3VTlhX0psc2gyNjVYMjZUck1wR0tFa1lIQVN4NmhQN0JFbUJGX2ZwUkl5YnJDeHpBRjU2UDBGeTc1cVZIUzYwZ3RVMnhOQ2tQMFBvZ2ZOS3RtSlA2eUV0dDdQRUd0V0R5bWdVTDMwQU9EenJ5N0pmTmVVOEs1VHdhTUFmTjFoYlkyNTdWMXJmRU4xcWRwbXZIUC1HRm1OSzMtejBKZl9xV0VHdnR3ZTBTWlhDVDZoX0tsQnNRZlpMVDcyLU1rMHlSbTRtWXc?oc=5","date":"2026-01-16","type":"regulatory","source":"Investing.com","summary":"Inotiv receives preliminary court approval for $2.49 million derivative settlement - Investing.com","headline":"Inotiv receives preliminary court approval for $2.49 million derivative settlement","sentiment":"positive"},{"date":"2026-01-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1zOEUyZU5mSlpzSTRwZ1JzRk1kaC1jYzZPVEpDMy0zald0UFR5UVpVN19Sb00zLW45OHlLVVJzcFFBVmxUNGFvTG9hQnVadmc0R2NwWnEzTGJ5YnFtMXMtc3FYU3VWZTEyWmJsUFU0ZkQyc1Nx?oc=5","date":"2025-12-09","type":"trial","source":"The HIPAA Journal","summary":"Pharmaceutical Firm Inotiv Discloses Ransomware Attack and Data Breach - The HIPAA Journal","headline":"Pharmaceutical Firm Inotiv Discloses Ransomware Attack and Data Breach","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"trial","source":"BleepingComputer","summary":"Pharma firm Inotiv discloses data breach after ransomware attack - BleepingComputer","headline":"Pharma firm Inotiv discloses data breach after ransomware attack","sentiment":"neutral"},{"date":"2025-12-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2025-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[{"drugName":"NOTV-001","drugSlug":"notv-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Charles River Laboratories","LabCorp","Eurofins Scientific"],"therapeuticFocus":["Oncology","Neurology"],"financials":{"source":"sec_edgar+yahoo","revenue":547656000,"revenuePeriod":"2022-09-30","revenueHistory":[{"value":547656000,"period":"2022-09-30"},{"value":89605000,"period":"2021-09-30"},{"value":89605000,"period":"2021-09-30"},{"value":60469000,"period":"2020-09-30"},{"value":60469000,"period":"2020-09-30"}],"grossProfit":120980000,"grossProfitHistory":[{"period":"2025-09-30","value":120980000},{"period":"2024-09-30","value":111171000},{"period":"2023-09-30","value":181942000},{"period":"2022-09-30","value":157212000}],"rdSpend":405000,"rdSpendHistory":[{"period":"2021-09-30","value":405000}],"sgaSpend":92244000,"operatingIncome":-36998000,"operatingIncomeHistory":[{"period":"2025-09-30","value":-36998000},{"period":"2024-09-30","value":-54462000},{"period":"2023-09-30","value":-9240000},{"period":"2022-09-30","value":20251000}],"netIncome":-68625000,"netIncomeHistory":[{"period":"2025-09-30","value":-68625000},{"period":"2024-09-30","value":-108445000},{"period":"2023-09-30","value":-105140000},{"period":"2022-09-30","value":-337018000}],"eps":-2.11,"epsHistory":[{"period":"2025-09-30","value":-2.11},{"period":"2024-09-30","value":-4.19},{"period":"2023-09-30","value":-4.1},{"period":"2022-09-30","value":-13.84}],"cash":21741000,"cashHistory":[{"period":"2025-09-30","value":21741000},{"period":"2024-09-30","value":21432000},{"period":"2023-09-30","value":35492000},{"period":"2022-09-30","value":18515000}],"totalAssets":771114000,"totalLiabilities":635086000,"totalDebt":459288000,"equity":136028000,"operatingCashflow":-10455000,"operatingCashflowHistory":[{"period":"2025-09-30","value":-10455000},{"period":"2024-09-30","value":-6805000},{"period":"2023-09-30","value":27883000},{"period":"2022-09-30","value":-5217000}],"capex":-16615000,"capexHistory":[{"period":"2025-09-30","value":-16615000},{"period":"2024-09-30","value":-22310000},{"period":"2023-09-30","value":-27503000},{"period":"2022-09-30","value":-36300000}],"freeCashflow":-27070000,"dividendsPaid":null,"buybacks":null,"employees":1945,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":23910000,"ebit":-16553000,"ebitda":-2762000,"period":"2025-12-31","revenue":120879000,"epsBasic":-0.83,"netIncome":-28378000,"rdExpense":null,"epsDiluted":-0.83,"grossProfit":24810000,"operatingIncome":-16144000},{"sga":22316000,"ebit":-7519000,"ebitda":6421000,"period":"2025-09-30","revenue":138142000,"epsBasic":-0.25,"netIncome":-8552000,"rdExpense":null,"epsDiluted":-0.25,"grossProfit":33029000,"operatingIncome":-6706000},{"sga":23409000,"ebit":-5156000,"ebitda":8829000,"period":"2025-06-30","revenue":130683000,"epsBasic":-0.51,"netIncome":-17577000,"rdExpense":null,"epsDiluted":-0.51,"grossProfit":33922000,"operatingIncome":-5530000},{"sga":22230000,"ebit":-2530000,"ebitda":11294000,"period":"2025-03-31","revenue":124323000,"epsBasic":-0.44,"netIncome":-14866000,"rdExpense":null,"epsDiluted":-0.44,"grossProfit":28991000,"operatingIncome":-9479000},{"sga":24289000,"ebit":-15970000,"ebitda":-1791000,"period":"2024-12-31","revenue":119876000,"epsBasic":-1.02,"netIncome":-27630000,"rdExpense":null,"epsDiluted":-1.02,"grossProfit":25038000,"operatingIncome":-15283000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.31,"previousClose":0.31,"fiftyTwoWeekHigh":3.32,"fiftyTwoWeekLow":0.22,"fiftyTwoWeekRange":"0.22 - 3.32","fiftyDayAverage":0.31,"twoHundredDayAverage":0.88,"beta":0,"enterpriseValue":479293888,"forwardPE":-6.2,"priceToBook":0.14,"priceToSales":0.02,"enterpriseToRevenue":0.94,"enterpriseToEbitda":298.62,"pegRatio":0,"ebitda":1605000,"ebitdaMargin":0.3,"freeCashflow":20620124,"operatingCashflow":354000,"totalDebt":483519008,"debtToEquity":627.1,"currentRatio":0.27,"returnOnAssets":-4.6,"returnOnEquity":-74.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":2,"targetMeanPrice":3.25,"targetHighPrice":5,"targetLowPrice":1.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":9,"institutionHeldPercent":19.3,"sharesOutstanding":34888147,"floatShares":32280607,"sharesShort":3134562,"shortRatio":3.27,"shortPercentOfFloat":9.1,"epsTrailing":-2.48,"epsForward":-0.05,"revenuePerShare":14.73,"bookValue":2.21,"officers":[{"age":65,"name":"Mr. Robert W. Leasure Jr.","title":"President, CEO & Director"},{"age":60,"name":"Ms. Beth A. Taylor CPA","title":"EVP & CFO"},{"age":47,"name":"Ms. Andrea M. Castetter","title":"EVP of General Counsel & Corporate Secretary and Chief Compliance Officer"},{"age":59,"name":"Dr. John E. Sagartz D.V.M., DiplomateACVP, Ph.D.","title":"Chief Strategy Officer & Director"},{"age":54,"name":"Dr. Adrian  Hardy Ph.D.","title":"Chief Commercial Officer"},{"age":38,"name":"Mr. Brennan  Freeman","title":"VP of Finance, Principal Accounting Officer & Corporate Controller"},{"age":58,"name":"Mr. John Gregory Beattie DSA","title":"Chief Operating Officer of DSA"},{"age":null,"name":"Ms. Lizanne  Muller","title":"Group President of RMS"}],"industry":"Diagnostics & Research","irWebsite":"http://www.basinc.com/invest/","website":"https://www.inotiv.com","phone":"765 463 4527"}}